EGF vs Palifermin
Head-to-head comparison of EGF (Human Epidermal Growth Factor) and Palifermin (Recombinant Human Keratinocyte Growth Factor (KGF, FGF7)) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | EGF | Palifermin |
|---|---|---|
| Category | Recovery & Healing | Recovery & Healing |
| Full Name | Human Epidermal Growth Factor | Recombinant Human Keratinocyte Growth Factor (KGF, FGF7) |
| Molecular Weight | 6.0 kDa | 16.3 kDa |
| Half-Life | minutes | 4–6 hours |
| Amino Acids | 53 | 140 |
| Typical Dose | 0.04–0.1 mg/cm²/day | 60 µg/kg/day |
| Route | Topical | Intravenous |
| Purity | ≥98% | ≥98% |
| Studies Count | 650 | 250 |
| Research Status | Clinical | Clinical |
EGF Benefits
- ✓re-epithelialization
- ✓fibroblast activation
- ✓angiogenesis support
- ✓faster ulcer closure
Palifermin Benefits
- ✓epithelial protection
- ✓mucosal regeneration
- ✓barrier restoration
- ✓reduced inflammatory injury
EGF Dosing
Topical daily|0.04–0.1 mg/cm²|short courses until granulation/closure
Palifermin Dosing
IV 60 µg/kg/day for 3 days before and 3 days after insult|research protocols vary|short courses only
EGF Side Effects
- ⚠local irritation
- ⚠erythema
- ⚠theoretical hyperproliferation
- ⚠pain at site
Palifermin Side Effects
- ⚠rash
- ⚠taste changes
- ⚠edema
- ⚠arthralgia
Research Overview
EGF
Human and animal studies show EGF can accelerate epithelial migration and wound closure, especially in burns, ulcers, and mucosal injury. Its best evidence is for topical or local delivery because systemic exposure is brief and the effect is highly localized.
Palifermin
Palifermin is clinically established for mucosal protection and has been studied for epithelial repair in other tissues. The strongest evidence is for epithelial resilience and regeneration rather than direct dermal remodeling.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.